Interval debulking in epithelial ovarian carcinomas: the past, present and the future.
Primary cytoreductive surgery followed by combination chemotherapy of paclitaxel and cisplatinum is the standard treatment for advanced staged epithelial ovarian cancers. Despite the maximal efforts to increase optimal cytoreductive success rates and related ultra-radical surgeries, five-year survival rates are still poor. Primary cytoreductive surgeries and their radicalities have been criticized since the early nineties. Interval debulking surgery (IDS) and neo-adjuvant chemotherapy (NAC) are the two suggested alternatives to the primary debulking approaches. In this article, the authors summarize and discuss the IDS approach with an associated literature review.
Gultekin
M
M
Department of Obstetrics and Gynecology, Cankiri Government Hospital, Cankiri, Turkey. mrtgultekin@yahoo.com
Diribas
K
K
Buru
E
E
Dursun
P
P
Yuce
K
K
Ayhan
A
A
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D003131:Combined Modality Therapy; D005260:Female; D005544:Forecasting; D013509:Gynecologic Surgical Procedures / Q000379:methods / Q000639:trends*; D006801:Humans; D020360:Neoadjuvant Therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate
D000970:Antineoplastic Agents